Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen
Information source: University of Chicago
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Rhinitis
Intervention: fluticasone furoate (Drug); fluticasone furoate placebo (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: University of Chicago Official(s) and/or principal investigator(s):
Robert Naclerio, MD, Principal Investigator, Affiliation: University of Chicago
Overall contact:
Marcy deTineo, BSN, Phone: 773-702-5889
Summary
The purpose of this study is to help us to a better understanding of how nose and eye
symptoms are related in patients with allergies.
Clinical Details
Official title: Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen
Study design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study
Primary outcome: The primary endpoint will be the difference in change in the level of tryptase after antigen challenge between fluticasone furoate and placebo
Secondary outcome: The difference in change in symptom scores after antigen challenge between fluticasone furoate and placebo
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Males and females between 18 and 45 years of age.
2. History of grass and/or ragweed allergic rhinitis.
3. Positive skin test to grass and/or ragweed antigen.
4. Positive response to screening nasal challenge.
Exclusion Criteria:
1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
2. Pregnant or lactating women.
3. Upper respiratory infection within 14 days of study start.
Locations and Contacts
Marcy deTineo, BSN, Phone: 773-702-5889
University of Chicago Medical Center, Chicago, Illinois 60637, United States
Additional Information
Starting date: November 2008
Last updated: November 14, 2008
|
